Immunotherapy with ponezumab for probable cerebral amyloid angiopathy

OBJECTIVE: Cerebral amyloid angiopathy (CAA) is caused by cerebrovascular deposition of β‐amyloid fragments leading to cerebrovascular dysfunction and other brain injuries. This phase 2, randomized, double–blind trial in patients with probable CAA assessed the efficacy and safety of ponezumab, a nov...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ann Clin Transl Neurol
Hauptverfasser: Leurent, Claire, Goodman, James A., Zhang, Yao, He, Ping, Polimeni, Jonathan R., Gurol, Mahmut Edip, Lindsay, Monica, Frattura, Linda, Sohur, Usharbudh Shivraj, Viswanathan, Anand, Bednar, Martin M., Smith, Eric E., Greenberg, Steven M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2019
Schlagworte:
Research Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6469253/
https://ncbi.nlm.nih.gov/pubmed/31020004
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.761
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge